Back to search results

Hand Transplant Study with Belatacept for Limb Loss

This study is exploring hand transplantation as a treatment for individuals who have lost a limb below the elbow. It aims to see if a hand transplant can improve your ability to perform daily activities. Researchers are also testing a medication called Nulojix® (belatacept), which is approved for kidney transplants, to help prevent the body from rejecting the new hand. To join, you should be between 18 and 65 years old and willing to travel for study visits. The main goal is to measure how well you can use the transplanted hand in daily life 18 months after the surgery. The study's current status is unclear.

Study design
This is an interventional study planning to enroll 50 participants. It is testing a hand transplant procedure and the drug Belatacept.
What's involved
You would have several study visits over 18 months, including medical history, vital signs, blood tests, X-rays, and biopsies. You would also need to travel to the study site or send samples by mail.
Compensation
Not stated in the trial record.
Follow-up
Your ability to use the transplanted limb will be measured at 18 months following transplantation.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT02310867

Immunomodulation to Optimize Vascularized Composite Allograft Integration for Limb Loss Therapy

Recruiting
PHASE2Ages 18–65InterventionalTreatment
Linda Cendales
~50 participants
Updated 2026-04-09 on ClinicalTrials.gov
What's tested:BelataceptHand transplant

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Ability to use the tranplanted limb in activities of daily living at 18 months following transplantation measured by a quantitative functional test.
Measured over 18 months

Conditions

Immunosuppression

Explore related trials

Amputation

NCT02310867

Where you'd take part

This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • Duke University Medical Center

    Durham, North Carolinano site contact published

    Recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • Linda Cendales, MD · PRINCIPAL_INVESTIGATOR · Duke University

Who to contact

Linda Cendales, MD
[email protected]
919-681-7514
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Exclusion

Any condition that precludes serial follow-up
Any condition that would likely increase the risk of protocol participation or confound the interpretation of the data
Any active malignancy or any history of a malignancy or lymphoma
Inability or unwillingness to comply with protocol monitoring and therapy and immunodeficiency syndrome(s)

What this trial measures

  • Ability to use the tranplanted limb in activities of daily living at 18 months following transplantation measured by a quantitative functional test.18 months